OneSource Specialty Pharma Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/p0eyix79gfczo8ge4dl9oppi.pdf

Key Takeaways


The FY28 Ambition and the Transition-Year Bridge

Arun Kumar: "So I strongly believe that we do not see any risk to our FY '28."

DDC: The Engine, the Pipeline, and the Capacity Bet

Arun Kumar: "So consequently, taking more customers at the cost of upsetting established customer relations is not something any CDMO, for that matter, we would do."

Market Openings and Launch Timelines


Pricing, Competition, and the Oral vs. Injectable Debate

Neeraj Sharma: "Lilly has very clearly mentioned that they expect the peak share of their oral product to be no more than 25% of the total anti-obesity market."

Financial Position and Capital Allocation


Operational Resilience and Compliance

Arun Kumar: "We all know that we are only as good as our next inspection."

Guidance & Commitments

CommitmentSpecificsTimeline
Organic revenue target$400 mnFY28
EBITDA margin target38–40%FY28
Revenue CAGR30%FY25 to FY28
Steady-state EBITDA margin40%Steady state (no date)
FY26 revenue patternH1 tepid, H2 strong; exit run-rate annualized in zip code of FY28 trajectoryFY26
FY27 growth profileSolid, consistent QoQ growth; first full year of Sema commercializationFY27
Rated capacity expansionFrom 4 crore to over 9 crore unitsBy December
Capex~$100 mn over next couple of yearsNext 2 years
Net debt targetNet debt freeNext 2–3 years
Debt-to-EBITDA ceilingBelow 1.5xMedium term
Fixed asset turnsAbove 2xOngoing
Liraglutide commercial launchDependent on customer readinessAs soon as next quarter
Teriparatide commercial launchApproval already in placeWithin FY26
First non-GLP DDC product (US) commercializationFirst-of-type peptide DDCFY26
First biologic peptide DDC (Europe) commercializationAlready approvedFY26
NBE commercializationFirst-in-class biologic2028–29
Semaglutide commercial supply startFrom freedom-to-operate perspective, if everything goes to planQ4 (calendar)
No additional GLP DDC customer onboardingTo avoid capacity clash with existing relationshipsUntil further notice

Key Metrics

MetricQ4 FY25
Revenue₹426 crore, +22% YoY
Full-year revenue₹1,444.9 crore, +30% YoY
EBITDA₹182.5 crore, +79% YoY
Full-year EBITDA₹466.5 crore, more than twice FY24
EBITDA margin43%
PAT₹99.2 crore, versus a loss in prior year
Full-year adjusted PAT₹93.6 crore, excluding one-timers
Annualized Q4 EPS₹48.9, fully diluted, excluding exceptional items and scheme-related intangibles
Full-year EPS₹21.4, fully diluted, excluding exceptional items and scheme-related intangibles
Full-year ROCE22.9%
Q4 annualized ROCE40.9%
Net debt₹470.7 crore, net of cash and cash equivalents
Interest cost₹27.8 crore, down 20% QoQ
Fixed asset turns1.9, anticipated to remain higher than 2
Customer logo count70+
DDC projects~50, in various stages of execution
DDC customers20+
Rated capacity expansionfrom 4 crore to a little over 9 crore, as early as December
Capex plan~$100 million, over the next couple of years
FY25–FY28 revenue growth CAGR guidance30%
Steady-state EBITDA margin guidance40%
FY28 revenue target$400 million
FY28 EBITDA margin target38% to 40%
Debt-to-EBITDA targetbelow 1.5, over the medium term
Net-debt-free targetnext 2 to 3 years